// App-Quantinova.ai

62 : A tumor growth rate/overall survival model for atezolizumab as an early predictor of OS in patients with first or second line metastatic urothelial carcinoma.

Researchers

Presenter

  • Rene Bruno

Principal Investigators

  • Laurent Claret

  • Benjamin Wu

  • Jin Y Jin

  • Helen Winter

  • Na Cui

  • Christina Louise Derleth

  • Xiaodong Shen

  • Sandhya Girish

  • Jonathan E. Rosenberg

  • Thomas Powles

Medical Centers

  • Roche/Genentech, Clinical Pharmacology, Marseille, France

  • Genentech-Roche, Peypin, France

  • Clinical Pharmacology, Genentech-Roche, South San Francisco, CA

  • Genentech, San Francisco, CA

  • Roche/Genentech, Clinical Pharmacology, San Francisco, CA

  • Genentech, Inc., South San Francisico, CA

  • Roche/Genentech, South San Francisco, CA

  • Genentech, Inc., South San Francisico, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Locations

  • France

  • United States

  • United Kingdom

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Atezolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved